



April 4, 2016

## **Abhay Joshi, PhD, MBA, Chief Operating Officer of Revance, Honored by the American Institute for Medical and Biological Engineering (AIMBE)**

**NEWARK, Calif., April 4, 2016** - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, proudly announces that its Chief Operating Officer Abhay Joshi, Ph.D., MBA, was inducted today to the American Institute of Medical and Biological Engineering (AIMBE) College of Fellows Class of 2016. Dr. Joshi was nominated and elected by peers and members of the College of Fellows for taking botulinum toxin from initial lab-scale production, formulation, GMP manufacturing, scale-up, and supply chain logistics to global commercialization and distribution.

"We congratulate Abhay on his election to the Institute's prestigious College of Fellows Class of 2016. Since joining Revance's executive team in December 2015, Abhay has been instrumental in developing plans to ramp up commercial manufacturing of our company's two unique botulinum toxin drug product candidates," said Revance's President and Chief Executive Officer Dan Browne. "We are delighted to see Abhay's leadership and expertise recognized, particularly by a peer group of distinguished bioengineers."

The College of Fellows is comprised of the top two percent of medical and biological engineers in the country. The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators, and successful entrepreneurs, comprise the College of Fellows.

AIMBE Fellows are recognized for their contributions in teaching, research, and advocacy to benefit society. AIMBE Fellows have been awarded the Presidential Medal of Science and the Presidential Medal of Technology and Innovation and many also are members of the National Academy of Engineering, National Academy of Medicine, and the National Academy of Sciences.

A formal induction ceremony was held during AIMBE's 25th Annual Meeting at the National Academy of Sciences Great Hall in Washington, DC today on April 4, 2016.

### **About The American Institute for Medical and Biological Engineering (AIMBE)**

AIMBE's mission is to recognize excellence in, and advocate for, the fields of medical and biological engineering in order to advance society. Since 1991, AIMBE's College of Fellows has led the way for technological growth and advancement in the fields of medical and biological engineering. Fellows have helped revolutionize medicine and related fields in order to enhance and extend the lives of people all over the world. They have also successfully advocated for public policies that have enabled researchers and business-makers to further the interests of engineers, teachers, scientists, clinical practitioners, and ultimately, patients. For more information, please visit <http://www.aimbe.org>

### **About Revance Therapeutics, Inc.**

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's trajectory to commercial success begins with the company's novel and proprietary TransMTS® carrier-peptide delivery system, which is uniquely designed to target and transport macromolecules to their desired location.

Revance's journey to market starts with the neurotoxin daxibotulinumtoxinA, the company's highly purified botulinum toxin type A. The TransMTS technology is used in the delivery of botulinum toxin through two novel drug product candidates: DaxibotulinumtoxinA Topical Gel (RT001) that permits needle-free application, and DaxibotulinumtoxinA for Injection (RT002), which is designed to enable targeted administration and long-lasting effect.

Revance is developing RT001 and RT002 for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles, excessive sweating and muscle movement disorders. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. Beyond botulinum toxin, Revance expects the TransMTS technology can be applied to transdermal, mid-dermal or deep tissue delivery of a variety of other macromolecules. More information on Revance can be found at [www.revance.com](http://www.revance.com).

*"Revance Therapeutics", TransMTS®, "Remarkable Science Changes Everything", and the Revance logo are registered*

*trademarks of Revance Therapeutics, Inc.*

###

**Contacts**

Investors:

Revance Therapeutics

Jeanie Herbert

(714) 325-3584

[jherbert@revance.com](mailto:jherbert@revance.com)

Burns McClellan

Ami Bavishi

212-213-0006

[abavishi@burnsmc.com](mailto:abavishi@burnsmc.com)

Trade Media:

Nadine Tosk

504.453.8344

[nadinepr@gmail.com](mailto:nadinepr@gmail.com)